CLLS sentiment intelligence

ETFs Investing in Cellectis S.A. Sponsored ADR Stocks

This article lists ETFs that include Cellectis S.A. Sponsored ADR stocks. It highlights the iShares Biotechnology ETF (IBB) as one such fund, providing its market value, weight, issuer, expense ratio, AUM, price, change, related volume, and 3-year NAV total return. The informatio

Tone

Neutral 50/100

Event

Market update

Published

16 Jul 2026 21:39

Source

TradingView

Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks

Tone

Neutral 50/100

Event

Earnings

Published

16 Jul 2026 18:49

Source

Market source

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Tone

Neutral 50/100

Event

Earnings

Published

13 Jul 2026 12:30

Source

Market source

Price to book forward of Cellectis S.A. – EURONEXT:ALCLS

This article provides the "Price to book forward" for Cellectis S.A. (Euronext: ALCLS). It indicates the financial metric for the company, accessible through TradingView's platform, and details the data sources for market and reference information. The content itself seems to be

Tone

Neutral 50/100

Event

Market update

Published

06 Jul 2026 00:40

Source

TradingView

Enterprise value to revenue forward of Cellectis S.A. – EURONEXT:ALCLS

This article focuses on the enterprise value to revenue forward for Cellectis S.A. (Euronext: ALCLS). The content, likely a financial data point or an analysis snippet, is presented within the context of TradingView's financial market platform.

Tone

Neutral 50/100

Event

Earnings

Published

05 Jul 2026 14:10

Source

TradingView

Price to book forward of Cellectis S.A. – NASDAQ:CLLS

This page provides financial information for Cellectis S.A. (NASDAQ: CLLS), specifically its price-to-book forward ratio. It briefly touches on the company's market data but does not include further details like the actual value or changes in the price-to-book ratio. The content

Tone

Neutral 50/100

Event

Market update

Published

05 Jul 2026 08:40

Source

TradingView

Cellectis monthly capital update shows 100.7M shares, 105.6M votes

Cellectis (CLLS) released its monthly capital update for June 30, 2026, reporting 100,698,158 shares outstanding and 105,551,650 voting rights on Euronext Growth. This update provides transparency on the company's capital structure, as required by the French financial markets aut

Tone

Neutral 50/100

Event

Market update

Published

02 Jul 2026 20:40

Source

Stock Titan

European ADRs Jumped As Biotech Led The Pack

European ADRs, representing foreign shares traded in the US, experienced a significant jump led by biotech companies. The S&P Europe Select ADR Index rose 2.21%, with Cellectis climbing 14% and BioNTech gaining 4.5%. This rise in ADRs can act as a "preview" for European markets w

Tone

Neutral 50/100

Event

Market update

Published

02 Jul 2026 15:40

Source

Finimize

Price to earnings forward of Cellectis S.A. – EURONEXT:ALCLS

This article displays the "Price to earnings forward" metric for Cellectis S.A. (Euronext:ALCLS) on the TradingView platform. The content is primarily a data placeholder within a financial information service, showing the company's ticker, market status, and indicating that the s

Tone

Neutral 50/100

Event

Earnings

Published

30 Jun 2026 23:39

Source

TradingView

Price to sales forward of Cellectis S.A. – EURONEXT:ALCLS

This article provides a brief mention of the "Price to sales forward" for Cellectis S.A. (EURONEXT:ALCLS) on the TradingView platform. It appears to be a stub or a section of a larger financial data presentation, indicating the availability of this specific financial metric. The

Tone

Neutral 50/100

Event

Market update

Published

30 Jun 2026 17:42

Source

TradingView

Price to earnings forward of Cellectis S.A. – FWB:ZVA

This article provides the "Price to earnings forward" value for Cellectis S.A. (FWB:ZVA) on the Frankfurt Stock Exchange. It indicates that no trades have occurred and the market is closed. The content primarily focuses on financial data for this specific company.

Tone

Neutral 50/100

Event

Earnings

Published

30 Jun 2026 04:40

Source

TradingView

Cellectis S.A. Actuals & Estimates (EURONEXT:ALCLS)

This article provides comprehensive financial data and analyst estimates for Cellectis S.A. (ALCLS) on EURONEXT. It details current stock performance, historical highs and lows, market capitalization, volatility, and future price forecasts from analysts. The report also includes

Tone

Neutral 50/100

Event

Analyst action

Published

26 Jun 2026 20:09

Source

TradingView

Shareholders of Cellectis (NASDAQ: CLLS) reject savings plan issue

Cellectis S.A. filed an amended Form 6-K to correct a clerical error regarding its Combined General Meeting of Shareholders on June 25, 2026. The amendment clarifies that Resolution 30, which dealt with delegating authority to increase share capital for an employee savings plan,

Tone

Neutral 50/100

Event

Market update

Published

26 Jun 2026 20:09

Source

Stock Titan

ZVA Forecast — Price Target — Prediction for 2027

This article provides a forecast for Cellectis S.A. (ZVA) stock, including analyst price targets, future earnings estimates, and historical price data. It details the company's financial metrics such as recent earnings per share, revenue, and net income, alongside its EBITDA and

Tone

Neutral 50/100

Event

Earnings

Published

26 Jun 2026 15:41

Source

TradingView

Cellectis S.A. Sponsored ADR Actuals & Estimates (NASDAQ:CLLS)

This article provides an overview of Cellectis S.A. (NASDAQ:CLLS) financial actuals and estimates as presented on TradingView. It highlights different financial statements like the income statement, balance sheet, and cash flow, allowing users to compare actual results with analy

Tone

Neutral 50/100

Event

Earnings

Published

26 Jun 2026 11:41

Source

TradingView

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

Cellectis held its shareholders general meeting on June 25, 2026, where resolutions 1 through 29 were adopted, and resolution 30 was rejected. Approximately 55.84% of voting rights were exercised, and the detailed results are available on the company's website. Cellectis is a cli

Tone

Neutral 50/100

Event

Earnings

Published

26 Jun 2026 08:41

Source

GlobeNewswire

Press Release: Cellectis Reports Results From Shareholders Meeting Held on June 25, 2026

Cellectis has reported the results of its Shareholders Meeting held on June 25, 2026. The meeting discussed and approved key resolutions regarding the company's governance and financial matters for the upcoming period.

Tone

Neutral 50/100

Event

Earnings

Published

25 Jun 2026 22:40

Source

Moomoo

Cellectis Shareholders Approve 2025 Accounts and Expand Capital-Raising Powers at June 25 Meeting

Tone

Neutral 50/100

Event

Market update

Published

25 Jun 2026 21:30

Source

TipRanks

Cellectis (CLLS) meeting backs capital issuance mandates but rejects employee savings share plan

Cellectis S.A. held its Combined General Meeting of Shareholders on June 25, 2026, where key financial items and capital increase delegations, including an “at-the-market” equity financing program on the U.S. market, were approved with strong shareholder support. Shareholders als

Tone

Neutral 50/100

Event

Market update

Published

25 Jun 2026 20:41

Source

Stock Titan

[6-K] Cellectis S.A. Current Report (Foreign Issuer) | CLLS SEC Filing - Form 6-K

Cellectis S.A. filed a Form 6-K reporting the results of its shareholders' general meeting held on June 25, 2026. The company announced that resolutions 1 through 29 were adopted, while resolution 30 was rejected, aligning with the board of directors' recommendations. Approximate

Tone

Neutral 50/100

Event

Earnings

Published

25 Jun 2026 20:41

Source

Stock Titan

Cellectis (CLLS) 10K Form and Latest SEC Filings 2026

This article provides an overview of Cellectis (CLLS) SEC filings, including a historical record of documents submitted since 2017. It details the types of filings such as 10-K, 10-Q, and 8-K, explaining their significance for investors. The article notes that Cellectis's most re

Tone

Neutral 50/100

Event

Market update

Published

12 Jun 2026 03:09

Source

MarketBeat

Cellectis reports strong CAR-T cancer trial data at EHA 2026

Cellectis (NASDAQ:CLLS) presented highly encouraging clinical trial data at the EHA 2026 Congress for its gene-edited, off-the-shelf CAR-T cancer therapies. The company reported a 100% overall response rate for its lead asset, lasme-cel, in a target group of leukemia patients, wi

Tone

Neutral 50/100

Event

Analyst action

Published

11 Jun 2026 12:39

Source

grafa.com